flow trial semaglutide kidney outcomes The rationale, design and baseline data of FLOW, a with once-weekly in people with type 2 diabetes and chronic kidney disease Potential kidney protective effects of

After blocking with 5% BSA, the sections were incubated with 1:200 anti-GLP-1 (ab23468, Abcam), followed by detection with secondary antibodies Alexa Fluor 488 conjugated goat antibody to mouse IgG (A-11029, ThermoFisher

ABOUT AUTHOR John Wick As a blog writer with years of experience in the healthcare industry, I have got what it takes to write well-researched content that adds value for the audience

Now, Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes

JCI Insight 2018;3.